233 related articles for article (PubMed ID: 27828716)
1. Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).
Palomo V; Martinez A
Expert Opin Ther Pat; 2017 Jun; 27(6):657-666. PubMed ID: 27828716
[TBL] [Abstract][Full Text] [Related]
2. Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2016-2019).
Roca C; Campillo NE
Expert Opin Ther Pat; 2020 Nov; 30(11):863-872. PubMed ID: 32841101
[TBL] [Abstract][Full Text] [Related]
3. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation.
Martinez A; Castro A; Dorronsoro I; Alonso M
Med Res Rev; 2002 Jul; 22(4):373-84. PubMed ID: 12111750
[TBL] [Abstract][Full Text] [Related]
4. Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions.
Saraswati AP; Ali Hussaini SM; Krishna NH; Babu BN; Kamal A
Eur J Med Chem; 2018 Jan; 144():843-858. PubMed ID: 29306837
[TBL] [Abstract][Full Text] [Related]
5. Substrate competitive GSK-3 inhibitors - strategy and implications.
Eldar-Finkelman H; Licht-Murava A; Pietrokovski S; Eisenstein M
Biochim Biophys Acta; 2010 Mar; 1804(3):598-603. PubMed ID: 19770076
[TBL] [Abstract][Full Text] [Related]
6. Natural and synthetic bioactive inhibitors of glycogen synthase kinase.
Khan I; Tantray MA; Alam MS; Hamid H
Eur J Med Chem; 2017 Jan; 125():464-477. PubMed ID: 27689729
[TBL] [Abstract][Full Text] [Related]
7. [A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors].
Liu SN; Shen ZF
Yao Xue Xue Bao; 2007 Dec; 42(12):1227-31. PubMed ID: 18338632
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological inhibitors of glycogen synthase kinase 3.
Meijer L; Flajolet M; Greengard P
Trends Pharmacol Sci; 2004 Sep; 25(9):471-80. PubMed ID: 15559249
[TBL] [Abstract][Full Text] [Related]
9. GSK-3 Inhibitors: A Double-Edged Sword? - An Update on Tideglusib.
Mathuram TL; Reece LM; Cherian KM
Drug Res (Stuttg); 2018 Aug; 68(8):436-443. PubMed ID: 29388174
[TBL] [Abstract][Full Text] [Related]
10. Design of glycogen synthase kinase-3 inhibitors: an overview on recent advancements.
Arfeen M; Bharatam PV
Curr Pharm Des; 2013; 19(26):4755-75. PubMed ID: 23260024
[TBL] [Abstract][Full Text] [Related]
11. The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases.
Amar S; Belmaker RH; Agam G
Curr Pharm Des; 2011; 17(22):2264-77. PubMed ID: 21736545
[TBL] [Abstract][Full Text] [Related]
12. Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease.
Golpich M; Amini E; Hemmati F; Ibrahim NM; Rahmani B; Mohamed Z; Raymond AA; Dargahi L; Ghasemi R; Ahmadiani A
Pharmacol Res; 2015 Jul; 97():16-26. PubMed ID: 25829335
[TBL] [Abstract][Full Text] [Related]
13. New insights into glycogen synthase kinase-3: A common target for neurodegenerative diseases.
Wang C; Cui Y; Xu T; Zhou Y; Yang R; Wang T
Biochem Pharmacol; 2023 Dec; 218():115923. PubMed ID: 37981175
[TBL] [Abstract][Full Text] [Related]
14. Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease.
Maqbool M; Mobashir M; Hoda N
Eur J Med Chem; 2016 Jan; 107():63-81. PubMed ID: 26562543
[TBL] [Abstract][Full Text] [Related]
15. Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs.
Martinez A
Med Res Rev; 2008 Sep; 28(5):773-96. PubMed ID: 18271054
[TBL] [Abstract][Full Text] [Related]
16. Glycogen synthase kinase-3 as drug target: from wallflower to center of attention.
Van Wauwe J; Haefner B
Drug News Perspect; 2003 Nov; 16(9):557-65. PubMed ID: 14702136
[TBL] [Abstract][Full Text] [Related]
17. Activator or inhibitor? GSK-3 as a new drug target.
Takahashi-Yanaga F
Biochem Pharmacol; 2013 Jul; 86(2):191-9. PubMed ID: 23643839
[TBL] [Abstract][Full Text] [Related]
18. Glycogen phosphorylase inhibitors: a patent review (2008 - 2012).
Gaboriaud-Kolar N; Skaltsounis AL
Expert Opin Ther Pat; 2013 Aug; 23(8):1017-32. PubMed ID: 23627914
[TBL] [Abstract][Full Text] [Related]
19. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
Avila J; Wandosell F; Hernández F
Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491
[TBL] [Abstract][Full Text] [Related]
20. Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic.
Medina M; Castro A
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):533-43. PubMed ID: 18600569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
